Role of trabectedin in the treatment of soft tissue sarcoma
| Autor: | Alexandre Christinat, Serge Leyvraz |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Oncology
medicine.medical_specialty Pathology medicine.medical_treatment Review Ecteinascidia turbinata chemotherapy lcsh:RC254-282 Internal medicine Medicine Pharmacology (medical) Trabectedin Dexamethasone Chemotherapy medicine.diagnostic_test biology business.industry Soft tissue sarcoma lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease biology.organism_classification Cell culture soft tissue sarcoma trabectedin Adult Aged Antineoplastic Combined Chemotherapy Protocols/administration & dosage Chromosomes Human Pair 14 Chromosomes Human Pair 4 Cytarabine/administration & dosage Dexamethasone/administration & dosage Disease-Free Survival Female Follow-Up Studies Genetic Heterogeneity Hemoglobins Humans Male Middle Aged Multiple Myeloma/drug therapy Multiple Myeloma/genetics Multivariate Analysis Prognosis Retrospective Studies Translocation Genetic Vincristine/administration & dosage beta 2-Microglobulin/blood Premedication business Liver function tests DNA-minor groove binder medicine.drug |
| Zdroj: | OncoTargets and therapy Oncotargets and Therapy, vol. 2, no. 9, pp. 105-113 OncoTargets and Therapy, Vol 2009, Iss default, Pp 105-113 (2009) |
| ISSN: | 1178-6930 |
| Popis: | Alexandre Christinat, Serge LeyvrazCentre Pluridisciplinaire d’Oncologie, University Hospital, Lausanne, SwitzerlandAbstract: Interest in marine natural products has allowed the discovery of new drugs and trabectedin (ET-743, Yondelis), derived from the marine tunicate Ecteinascidia turbinata, was approved for clinical use in 2007. It binds to the DNA minor groove leading to interferences with the intracellular transcription pathways and DNA-repair proteins. In vitro antitumor activity was demonstrated against various cancer cell lines and soft tissue sarcoma cell lines. In phase I studies tumor responses were observed also in osteosarcomas and different soft tissue sarcoma subtypes. The most common toxicities were myelosuppression and transient elevation of liver function tests, which could be reduced by dexamethasone premedication. The efficacyof trabectedin was established in three phase II studies where it was administered at 1.5 mg/m2 as a 24 h intravenous infusion repeated every three weeks, in previously treated patients. The objective response rate was 3.7%–8.3% and the tumor control rate (which included complete response, partial response and stable disease) was obtained in half of patients for a median overall survival reaching 12 months. In nonpretreated patients the overall response rate was 17%. Twenty-four percent of patients were without progression at six months. The median overall survival was almost 16 months with 72% surviving at one year. Predictive factors of response are being explored to identify patients who are most likely to respond to trabectedin. Combination with other agents are currently studied with promising results. In summary trabectedin is an active new chemotherapeutic agents that has demonstrated its role in the armamentarium of treatments for patients with sarcomas.Keywords: soft tissue sarcoma, trabectedin, chemotherapy, DNA-minor groove binder |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|